Tag: assay

Oncotarget News

Figure 8: Major analytical performance measurements of the NeXT Personal® assay.

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

March 20, 2024

These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”BUFFALO, NY- March 20, 2024 – A new research paper was published in... read more

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Oncotarget

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.”BUFFALO, NY- September 19, 2023 – A new research paper was... read more

Figure 5: Correlation between observed AF and expected AF for 401 cancer-associated genes in a tumor tissue sample diluted with the corresponding normal specimen. NeXT Dx™

Oncotarget

Validation of a Comprehensive Genomic Profiling Assay: NeXT Dx™

August 30, 2023

NeXT Dx incorporates a range of features and comprehensive genome variant detection methods that lead to improved disease management and possible enhanced clinical utility.” BUFFALO, NY- August 30, 2023 –... read more